Central Nervous System Stimulants
"Central Nervous System Stimulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
| Descriptor ID |
D000697
|
| MeSH Number(s) |
D27.505.696.282 D27.505.954.427.220
|
| Concept/Terms |
Analeptics- Analeptics
- Analeptic Drugs
- Drugs, Analeptic
- Analeptic Agents
- Agents, Analeptic
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Stimulants".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Stimulants".
This graph shows the total number of publications written about "Central Nervous System Stimulants" by people in this website by year, and whether "Central Nervous System Stimulants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 6 | 4 | 10 |
| 2006 | 7 | 0 | 7 |
| 2007 | 11 | 2 | 13 |
| 2008 | 5 | 3 | 8 |
| 2009 | 4 | 0 | 4 |
| 2010 | 9 | 3 | 12 |
| 2011 | 5 | 6 | 11 |
| 2012 | 4 | 1 | 5 |
| 2013 | 7 | 2 | 9 |
| 2014 | 5 | 2 | 7 |
| 2015 | 7 | 2 | 9 |
| 2016 | 1 | 3 | 4 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Stimulants" by people in Profiles.
-
Killeen TK, Wolf B, Greer TL, Carmody T, Rethorst CD, Trivedi MH. Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study. Addict Behav. 2020 11; 110:106546.
-
Adisetiyo V, Gray KM, Jensen JH, Helpern JA. Brain iron levels in attention-deficit/hyperactivity disorder normalize as a function of psychostimulant treatment duration. Neuroimage Clin. 2019; 24:101993.
-
Patrick KS, Rodriguez W. Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography. Drug Metab Dispos. 2019 07; 47(7):764-767.
-
Pena-Bravo JI, Penrod R, Reichel CM, Lavin A. Methamphetamine Self-Administration Elicits Sex-Related Changes in Postsynaptic Glutamate Transmission in the Prefrontal Cortex. eNeuro. 2019 Jan-Feb; 6(1).
-
Larson TA, Winkler MC, Stafford J, Levis SC, O'Neill CE, Bachtell RK. Role of dopamine D2-like receptors and their modulation by adenosine receptor stimulation in the reinstatement of methamphetamine seeking. Psychopharmacology (Berl). 2019 Apr; 236(4):1207-1218.
-
Patrick KS, Radke JL, Raymond JR, Koller L, Nguyen LV, Rodriguez W, Straughn AB. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy. 2019 06; 39(6):677-688.
-
Peters J, Scofield MD, Reichel CM. Chemogenetic activation of the perirhinal cortex reverses methamphetamine-induced memory deficits and reduces relapse. Learn Mem. 2018 09; 25(9):410-415.
-
Richards C, Iosifescu DV, Mago R, Sarkis E, Geibel B, Dauphin M, McIntyre RS, Weisler R, Brawman-Mintzer O, Gu J, Madhoo M. A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. J Clin Psychopharmacol. 2018 Aug; 38(4):336-343.
-
Hu L, Matthews A, Shmueli-Blumberg D, Killeen TK, Tai B, VanVeldhuisen P. Prevalence of obesity for opioid- and stimulant-dependent participants in substance use treatment clinical trials. Drug Alcohol Depend. 2018 09 01; 190:255-262.
-
Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.